Interleukin 17

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
Lundi, juin 5, 2023
National Psoriasis Foundation, Psoriatic arthritis, Disease, Human, Asthma, Therapy, Macular degeneration, IBD, University Medical Center, Hook effect, Inflammation, Max Planck Society, COVID-19, Psoriasis, Interleukin 17, BVXV, COVID, Max Planck Institute for Multidisciplinary Sciences, IL-17A, Light, VHH, Patient, Patent, Hidradenitis suppurativa, MPG, UMG, Mab, Max Planck, Knowledge, Cytokine, Transport, BiondVax, Skin, Autoimmunity, Pharmaceutical industry, Vaccine

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

Biosimilar Interleukins Global Market Report 2022: Rising Prevalence of Autoimmune Conditions Spurring Growth - ResearchAndMarkets.com

Retrieved on: 
Mardi, novembre 8, 2022
Health, Pharmaceutical, Acquisition, Distribution, Pharmacy, Johns Hopkins University, Degenerative disease, Growth, Application, Population, IBD, IL-5, Cancer, Sanofi, Asthma, Rheumatoid arthritis, IL-6, Interleukin 17, Interleukin, Psoriasis, Cystine, Prevalence, Cell, Autoimmune disease, Inflammatory bowel disease, Generic drug, Vaccine

The "Biosimilar Interleukins Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Interleukins Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.
  • The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period.
  • Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.
  • Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders.

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

Retrieved on: 
Lundi, mars 2, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Autoimmune diseases, Psoriasis, RTT, Inflammation, Inflammatory cytokine, Cytokine, Interleukin 17, Ustekinumab

IL-6 and IL-8 are well-established mediators of potentially harmful effects in patients with inflammatory diseases and these data support the therapeutic potential of EDP1815 to treat classic inflammatory diseases such as psoriasis.

Key Points: 
  • IL-6 and IL-8 are well-established mediators of potentially harmful effects in patients with inflammatory diseases and these data support the therapeutic potential of EDP1815 to treat classic inflammatory diseases such as psoriasis.
  • Evelo previously reported interim data showing reduced production of systemic markers of inflammation in individuals with mild to moderate psoriasis dosed with EDP1815.
  • The detailed analysis of the previously reported data show that EDP1815 highlights the individual inflammatory cytokines and chemokines that were modulated.
  • Evelo currently has four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer.

AllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors

Retrieved on: 
Mercredi, septembre 11, 2019
Organ systems, Medical specialties, Autoimmune diseases, Medicine, Psoriasis, RTT, Interleukins, Interleukin 17, Walgreens, Psoriatic arthritis

ORLANDO, Fla., Sept. 11, 2019 /PRNewswire/ -- AllianceRx Walgreens Prime announced results from a new study analyzing data from patients prescribed interleukin-17 (IL-17) inhibitors for psoriasis.

Key Points: 
  • ORLANDO, Fla., Sept. 11, 2019 /PRNewswire/ -- AllianceRx Walgreens Prime announced results from a new study analyzing data from patients prescribed interleukin-17 (IL-17) inhibitors for psoriasis.
  • Patients reported improvements in psoriatic symptoms and demonstrated increased medication adherence after switching to one of the three IL-17 medications included in the study.
  • The study was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime.
  • Psoriasis is a chronic disease characterized by raised, red, scaly patches, or lesions on the skin which are often itchy and painful.

Global Growth Factors (Blood & Tissue) Market 2016-2024 with a Comparison of Erythropoietin-Based Drugs in the U.S. and European Union

Retrieved on: 
Jeudi, juin 13, 2019
Organ systems, Cytokines, Autoimmune diseases, Medical specialties, Branches of biology, Interleukins, Psoriasis, RTT, Interleukin 17, Interferon, Hepatitis C and HIV coinfection, IL17A

Interleukin-17 Market for Psoriasis Treatment: Positive Opportunities

Key Points: 

Interleukin-17 Market for Psoriasis Treatment: Positive Opportunities
Anti-IL-6 Pathways for RA Treatment: Favorable Prospects
Interferon-based Drugs for HCV Treatment: An Insight

Nuevolution Discloses the Identity of its "Cytokine X" Program being Interleukin IL-17A and Initiates Promotion of its Small Molecule IL-17A Inhibitor Program Targeting Inflammatory Diseases

Retrieved on: 
Mercredi, août 22, 2018
Interleukins, Cytokine, Interleukin, Medicine, IL17A, Interleukin 17

Today, Nuevolution AB (publ) announced the identity of its "Cytokine X" program being a lead discovery program targeting inhibition of Interleukin IL-17A using small molecules.

Key Points: 
  • Today, Nuevolution AB (publ) announced the identity of its "Cytokine X" program being a lead discovery program targeting inhibition of Interleukin IL-17A using small molecules.
  • The company also announced that it will initiate promotion for potential partnership opportunities on this exciting program targeting multiple inflammatory diseases.
  • Our data also supports that a small molecule directly targeting IL-17A, may achieve the same efficacy in clinical scoring as a therapeutic antibody directed against IL-17A.
  • "Important and disease relevant protein-protein interfaces, like the one we target here in our IL-17A program, are notoriously difficult to inhibit with small molecules.

Growth Factors (Blood and Tissue) - 2018 Global Strategic Business Report Analysis & Forecasts (2016-2024) - Burgeoning Global Population Offers Significant Growth Opportunities

Retrieved on: 
Vendredi, mai 18, 2018
Medicine, Cytokines, Clinical medicine, Interleukins, Psoriasis, RTT, Erythropoietin, Interleukin 17, Interferon

Increasing Healthcare Spending in Emerging Markets: Opportunities in Store

Key Points: 
  • Increasing Healthcare Spending in Emerging Markets: Opportunities in Store
    Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy
    Interleukin-17 Market for Psoriasis Treatment: Positive Opportunities
    Anti-IL-6 Pathways for RA Treatment: Favorable Prospects
    Interferon-based Drugs for HCV Treatment: An Insight